| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Endocrinology (H.F.E.-M., J.I.B.-C., F.A.-B., J.S.) and Molecular Genetics (J.L.S.M.), Hospital Ramón y Cajal, Madrid E-28034, Spain
Address all correspondence and requests for reprints to: Dr. Héctor F. Escobar-Morreale, Department of Endocrinology, Hospital Ramón y Cajal, Carretera de Colmenar km 9'1, Madrid E-28034, Spain. E-mail: hescobarm.hrc{at}salud.madrid.org.
Context: The polycystic ovary syndrome (PCOS) is frequently associated with obesity. However, there are very few data about PCOS in morbid obesity, especially with regard to its evolution after bariatric surgery.
Objective: The objective of this study was to evaluate the response of PCOS to the sustained and marked weight loss achieved by bariatric surgery in morbidly obese women.
Design: This was a longitudinal prospective nonrandomized evaluation.
Settings: The study was performed at an academic hospital.
Patients: Thirty-six consecutive premenopausal women submitted to bariatric surgery were screened for PCOS, which was present in 17.
Interventions: Bariatric surgery was performed.
Main Outcome Measures: Hyperandrogenism, menstrual function, and insulin resistance were estimated before and at least 6 months after bariatric surgery in 12 patients with PCOS.
Results: Weight loss (41 ± 9 kg after 12 ± 5 months) was paralleled by decreases in the hirsutism score (from 9.5 ± 6.8 to 4.9 ± 4.2; P = 0.001), total (69 ± 32 to 42 ± 19 ng/dl; P < 0.02) and free testosterone (from 1.6 ± 0.7 to 0.6 ± 0.3 ng/dl; P < 0.005), androstenedione (from 4.1 ± 1.5 to 3.0 ± 0.9 ng/ml; P < 0.02), and dehydroepiandrosterone sulfate (from 2000 ± 1125 to 1353 ± 759 ng/ml; P < 0.005); amelioration of insulin resistance estimated by homeostasis model assessment (from 6.0 ± 3.0 to 1.6 ± 1.0; P < 0.001); and restoration of regular menstrual cycles and/or ovulation in all patients.
Conclusions: The PCOS is a frequent finding in women with morbid obesity and may resolve after weight loss induced by bariatric surgery.
This article has been cited by other articles:
 |
|
 |
|
  R. L. Barbieri Update in Female Reproduction: A Life-Cycle Approach J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2439 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Corton, J. I. Botella-Carretero, J. A. Lopez, E. Camafeita, J. L. San Millan, H. F. Escobar-Morreale, and B. Peral Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry Hum. Reprod., March 1, 2008; 23(3): 651 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens Consensus on infertility treatment related to polycystic ovary syndrome Hum. Reprod., March 1, 2008; 23(3): 462 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Barbieri Clomiphene Versus Metformin for Ovulation Induction in Polycystic Ovary Syndrome: The Winner Is .... J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3399 - 3401. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mohlig, M. O Weickert, E. Ghadamgadai, A. Machlitt, B. Pfuller, A. M Arafat, A. F H Pfeiffer, and C. Schofl Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women Eur. J. Endocrinol., August 1, 2007; 157(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
